STERIS (STE) Projected to Post Earnings on Thursday

STERIS (NYSE:STE) is anticipated to post its quarterly earnings results before the market opens on Thursday, February 6th. Analysts expect STERIS to post earnings of $2.33 per share and revenue of $1.38 billion for the quarter. STERIS has set its FY25 guidance at $9.05-$9.25 EPS and its FY 2025 guidance at 9.050-9.250 EPS.Persons that are interested in participating in the company’s earnings conference call can do so using this link.

STERIS (NYSE:STE) last released its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.12 by $0.02. The business had revenue of $1.33 billion for the quarter, compared to the consensus estimate of $1.33 billion. STERIS had a return on equity of 13.78% and a net margin of 8.02%. The company’s revenue was up 7.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.03 EPS. On average, analysts expect STERIS to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

STERIS Stock Down 0.2 %

NYSE STE opened at $220.66 on Thursday. The stock has a 50 day moving average price of $211.90 and a 200-day moving average price of $224.77. STERIS has a one year low of $197.82 and a one year high of $248.24. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.55 and a current ratio of 2.41. The company has a market capitalization of $21.78 billion, a P/E ratio of 50.38 and a beta of 0.84.

STERIS Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 21st. Shareholders of record on Thursday, February 20th will be given a dividend of $0.57 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $2.28 annualized dividend and a yield of 1.03%. STERIS’s dividend payout ratio (DPR) is currently 52.05%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on STE shares. StockNews.com downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 29th. JMP Securities restated a “market outperform” rating and set a $265.00 price objective on shares of STERIS in a research report on Monday, November 18th. Piper Sandler raised STERIS from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $230.00 to $260.00 in a research note on Thursday, October 24th. Stephens reissued an “overweight” rating and set a $260.00 target price on shares of STERIS in a research report on Thursday, November 7th. Finally, Needham & Company LLC restated a “hold” rating on shares of STERIS in a research report on Friday, November 8th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $262.50.

Insider Transactions at STERIS

In other news, SVP Cary L. Majors sold 1,682 shares of the business’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $217.32, for a total transaction of $365,532.24. Following the completion of the sale, the senior vice president now directly owns 11,372 shares of the company’s stock, valued at approximately $2,471,363.04. The trade was a 12.88 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.14% of the company’s stock.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.